Clinical Response to Prostate Cancer Immunotherapy using GM-CSF and anti-CD152 Correlates with Diversity of Upmodulated Antibody Binding to Microarray Antigens

By /

“Diversity of Antigen-Specific Responses Induced In Vivo with CTLA-4 Blockade in Prostate Cancer Patients”   Kwek S S, L Fong, et al. (Oct 2012)  J Immunol 189(7): 3759-3766.

 “…advanced prostate cancer patients who clinically respond to treatment also develop enhanced Ab responses to a higher number of Ags than nonresponders…”

Relevant Ancell Products

Anti-CD152(CTLA-4) blocking mAb

Recombinant CD152-muIg

Recombinant CD80-muIg

Recombinant CD86-muIg